Last reviewed · How we verify

SK Plasma Co., Ltd. — Portfolio Competitive Intelligence Brief

SK Plasma Co., Ltd. pipeline: 0 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
SKP-0141 SKP-0141 phase 3 Recombinant fusion protein / Hemostatic agent Hematology
LIV-GAMMA SN Inj.10% LIV-GAMMA SN Inj.10% phase 3 Intravenous immunoglobulin (IVIG) Fc receptors, complement system, pathogenic antigens Immunology, Hematology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. ADMA Biologics, Inc. · 1 shared drug class
  2. Baxalta now part of Shire · 1 shared drug class
  3. Bio Products Laboratory · 1 shared drug class
  4. Biotest · 1 shared drug class
  5. CSL Behring · 1 shared drug class
  6. CSL Limited · 1 shared drug class
  7. Grifols Biologicals, LLC · 1 shared drug class
  8. Grifols Therapeutics LLC · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for SK Plasma Co., Ltd.:

Cite this brief

Drug Landscape (2026). SK Plasma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sk-plasma-co-ltd. Accessed 2026-05-17.

Related